Hims & Hers Health (NYSE:HIMS) Stock Price Down 7.3% - Should You Sell?

Hims & Hers Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Hims & Hers shares fell 7.3% to about $17.20, with trading volume roughly 75% below its average.
  • The company missed quarterly earnings and revenue estimates: EPS was $0.03 versus $0.06 expected, and revenue was $890.37 million versus $893.13 million expected. Revenue nevertheless grew 48.6% year over year.
  • Analysts have a consensus Hold rating and an average price target of $31.53; recent target changes were mixed, including cuts from Needham and Jefferies.
  • Interested in Hims & Hers Health? Here are five stocks we like better.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price dropped 7.3% on Tuesday. The company traded as low as $17.25 and last traded at $17.2030. Approximately 5,529,756 shares traded hands during trading, a decline of 75% from the average session volume of 22,187,676 shares. The stock had previously closed at $18.56.

Analysts Set New Price Targets

Several research firms have recently weighed in on HIMS. Needham & Company LLC reduced their target price on shares of Hims & Hers Health from $42.00 to $32.00 and set a "buy" rating for the company in a research note on Tuesday, November 10th. Jefferies Financial Group dropped their price target on shares of Hims & Hers Health from $31.00 to $24.00 and set a "hold" rating on the stock in a research note on Tuesday, November 10th. Bank of America raised their price objective on shares of Hims & Hers Health from $30.00 to $32.00 and gave the stock a "neutral" rating in a report on Tuesday, August 11th. Barclays reduced their price objective on shares of Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating for the company in a research note on Friday, August 21st. Finally, JPMorgan Chase & Co. started coverage on shares of Hims & Hers Health in a report on Friday, September 11th. They set a "neutral" rating and a $32.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $31.53.

Check Out Our Latest Analysis on HIMS

Hims & Hers Health Price Performance

The business's 50-day moving average price is $27.43 and its 200 day moving average price is $26.65. The company has a market capitalization of $4.12 billion, a P/E ratio of -21.25 and a beta of 2.53. The company has a quick ratio of 0.87, a current ratio of 0.92 and a debt-to-equity ratio of 3.85.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.03). The firm had revenue of $890.37 million during the quarter, compared to analysts' expectations of $893.13 million. Hims & Hers Health had a negative return on equity of 9.62% and a negative net margin of 6.65%. The business's revenue for the quarter was up 48.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.06 earnings per share. Analysts anticipate that Hims & Hers Health, Inc. will post -0.21 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 2,000 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $29.70, for a total value of $59,400.00. Following the transaction, the chief financial officer owned 234,527 shares of the company's stock, valued at $6,965,451.90. This represents a 0.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 3,462 shares of the firm's stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $27.60, for a total transaction of $95,551.20. Following the sale, the insider owned 293,886 shares in the company, valued at approximately $8,111,253.60. This trade represents a 1.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 107,744 shares of company stock worth $3,098,017 over the last three months. 11.76% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in HIMS. Versant Capital Management Inc boosted its stake in Hims & Hers Health by 801.2% in the second quarter. Versant Capital Management Inc now owns 748 shares of the company's stock worth $26,000 after buying an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in shares of Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company's stock worth $27,000 after acquiring an additional 319 shares in the last quarter. GK Wealth Management LLC bought a new stake in shares of Hims & Hers Health in the 3rd quarter worth approximately $37,000. Compass Financial Management LLC bought a new stake in shares of Hims & Hers Health in the 2nd quarter worth approximately $50,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Hims & Hers Health in the 2nd quarter valued at $147,000. Institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Hims & Hers Health Right Now?

Before you consider Hims & Hers Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.

While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines